Clinical trials: Advanced Malignant Tumors
Metastatic Melanoma
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
The primary objective of this study is to determine the response rate, duration of response,progression-free survival and overall survival of subjects with advanced melanoma treated with TH-302.
- Trial name
- NCT01864538
- Testing
- TH-302
- Where
- 7 sites in United States, Canada
- Volunteers
- 11 people
- Sponsor
- ImmunoGenesis
Melanoma (Skin), Cutaneous Melanoma
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or…
- Conditions
- Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor
- Trial name
- NCT05578872
- Testing
- ANV419
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 29 people
- Sponsor
- Anaveon AG
Lung Neoplasm Malignant
Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer
The goal of this clinical trial is to evaluate safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer (NSCLC) who are treatment-naïve and indicated for first-line…
- Trial name
- AFFINITY (NCT05890872)
- Testing
- Aliya Pulsed Electric Fields (PEF)
- Where
- 5 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Galvanize Therapeutics, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR-214 in adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NKTR-214 (NCT02869295)
- Testing
- NKTR-214
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Nektar Therapeutics
Locally Advanced or Metastatic Solid Tumors
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
This is a multicenter, open-label, Phase Ib/II clinical trial to evaluate the safety, tolerability, and antitumor efficacy of IN10018 in combination with pegylated liposomal doxorubicin (PLD) or IN10018 in combination with PLD…
- Trial name
- NCT05830539
- Testing
- IN10018+PLD, IN10018+PLD+Toripalimab
- Where
- 7 sites in China
- Volunteers
- 68 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Renal Cell Carcinoma, Ovarian Cancer
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended…
- Conditions
- Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer, Metastatic Cancer
- Trial name
- NCT06010875
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Gastrointestinal Cancer, Gastrointestinal Neoplasms
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e., locally advanced and unresectable, or metastatic) previously treated colorectal…
- Conditions
- Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer, Colorectal Neoplasms
- Trial name
- NCT03597581
- Testing
- ompenaclid, FOLFIRI, Bevacizumab
- Where
- 17 sites in United States
- Volunteers
- 89 people
- Sponsor
- Inspirna, Inc.
Neoplasm Malignant, Renal Cell Carcinoma
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination…
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- STELLAR-001 (NCT03845166)
- Testing
- XL092, Atezolizumab, Avelumab
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 325 people
- Sponsor
- Exelixis
Advanced Solid Tumors
A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors
A study of sequential administration of oral sapacitabine and oral Seliciclib in patients with advanced solid tumors.
- Trial name
- NCT00999401
- Testing
- sapacitabine and seliciclib
- Where
- 2 sites in United States
- Volunteers
- 103 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Advanced Malignant Tumor
A Study of Bispecific Antibody QLS31901 in Patients With Advanced or Metastatic Malignancies
This is a Phase 1, open label, non-randomised, dose-escalation single agent study with expansion cohorts for dose confirmation/safety and preliminary efficacy of QLS31901 in advanced or metastatic malignancies
- Trial name
- NCT04954456
- Testing
- QLS31901
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Solid Organ Tumors
An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors
First in human, open-label, sequential dose escalation and expansion study of intravenous BAL101553 in adult patients with advanced solid tumors.
- Trial name
- NCT01397929
- Testing
- BAL101553
- Where
- 3 sites in United Kingdom
- Volunteers
- 73 people
- Sponsor
- Basilea Pharmaceutica
Lymphoma, Malignant, Hodgkin's Lymphoma
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
This is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given alone once daily by mouth to subjects with advanced lymphoid malignancies.
- Conditions
- Lymphoma, Malignant, Hodgkin's Lymphoma, B Cell Lymphoma
- Trial name
- NCT00741871
- Testing
- SB1518
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- S*BIO
Advanced Solid Tumor, Metastatic Solid Tumor
A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas
This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma
- Trial name
- PROBE (NCT04986865)
- Testing
- ATG-101
- Where
- 8 sites in United States, Australia
- Volunteers
- 31 people
- Sponsor
- Antengene Biologics Limited
Advanced Solid Malignant Tumors
Open Label Study of DS-5573a
This is an open-label, sequential dose escalation and expansion study to evaluate the safety, and pharmacokinetics of DS-5573a in Japanese patients with advanced solid malignant tumors.
- Trial name
- NCT02192567
- Testing
- DS-5573a
- Where
- Japan
- Volunteers
- 19 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Melanoma, Thyroid Cancer
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
The study objective is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered PLX8394 in patients with advanced solid tumors.
- Conditions
- Melanoma, Thyroid Cancer, Colorectal Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT02012231
- Testing
- PLX8394
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Fore Biotherapeutics
Cancer, Solid Tumors
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
The purpose of this research study is to find the answers to the following questions: 1. What are the highest doses of CBP501 and cisplatin that can be safely administered as consecutive 2-hours and 1-hour infusions every 21…
- Trial name
- NCT00551512
- Testing
- CBP501 and Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- CanBas Co. Ltd.
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Advanced Solid Tumors
ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors
This is a Phase 1/2, multi-center, open-label study of CPI-1205 + ipilimumab in patients with histologically or cytologically confirmed advanced solid tumors.
- Trial name
- NCT03525795
- Testing
- CPI-1205, ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Constellation Pharmaceuticals
Advanced Solid Tumors
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
This is a single-arm, open-label, multicenter, phase II study of CVL237 tablets in the treatment of advanced solid tumors with PTEN deficiency.
- Trial name
- NCT06183736
- Testing
- CVL237 tablets
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Solid Tumors, Lymphoma
Evaluation of KX2-391 in Patients With Advanced Malignancies
The purpose of this Phase 1 study is to determine the safety and tolerability of KX2-391 in cancer patients.
- Trial name
- NCT00658970
- Testing
- KX2-391
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Athenex, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.